Dual Action Antibacterial Compounds Against Resistant Pathogens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The widespread of drug-resistant bacterial strains poses a significant challenge in treating bacterial infections, as existing antibiotics are ineffective against resistant pathogens and can lead to the development of further resistance, necessitating the design of new molecules that can combat both existing and emerging resistant bacteria.
Innovation Solution
A rational structure-based drug discovery approach, known as 'Dual Action Rational Therapeutics,' which involves fragment-based in silico drug design and novel chemical modifications of existing antibiotics to create compounds that can bypass or suppress antibiotic resistance mechanisms, targeting multiple sites and inhibiting biofilm formation to ensure effective antibacterial activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics are used to treat bacterial infections, then treatment is provided, but drug-resistant bacterial strains evade the antibiotic action and resistance develops
Solution Approach 1:
The patent divides the antibacterial action into multiple independent mechanisms: (1) inhibition of cell wall synthesis, (2) disruption of membrane permeability, (3) inhibition of protein synthesis, and (4) interference with DNA replication. Each mechanism targets different bacterial processes, ensuring that resistance to one mechanism does not confer resistance to others, thereby maintaining reliable antibacterial efficacy against diverse and resistant strains.
Solution Approach 2:
The patent designs a multi-functional antibacterial agent that simultaneously performs multiple functions: it acts as a cell wall synthesis inhibitor, a membrane permeability disruptor, a protein synthesis inhibitor, and a DNA replication interferent. This universal action across multiple bacterial processes ensures effective treatment regardless of the specific resistance mechanisms employed by different bacterial strains.
2Reliability
If new molecules are designed to combat resistant bacteria, then antibacterial activity is improved, but the complexity of drug discovery and synthesis increases
Solution Approach 1:
The patent performs preliminary computational modeling and molecular docking simulations before actual synthesis to predict the binding affinity and mechanism of action of potential antibacterial compounds. This preliminary digital screening identifies promising candidates that can overcome resistance mechanisms, reducing the number of compounds that need to be physically synthesized and tested, thereby managing the complexity of the drug discovery process.
Solution Approach 2:
The patent systematically varies key molecular parameters such as molecular weight, lipophilicity, hydrogen bonding capacity, and spatial configuration to optimize the antibacterial activity and penetration through biofilms. By methodically adjusting these parameters based on structure-activity relationship (SAR) data, the patent identifies optimal molecular structures that effectively combat resistant bacteria while managing synthesis complexity through predictable structure-performance relationships.
3Reliability
If antibiotics are used to treat infections, then bacterial growth is inhibited, but biofilms form and protect bacteria from antibiotic access
Solution Approach 1:
The patent extracts and targets the specific functions that enable biofilm formation and protection: it inhibits the synthesis of biofilm matrix components, disrupts the adhesive properties of biofilms, and creates permeability defects in biofilm structures. By removing these protective capabilities, the patent enables antibiotic access to embedded bacteria and maintains reliable infection treatment despite biofilm presence.
Solution Approach 2:
The patent transitions from conventional single-mode antibacterial action to multi-dimensional action: it acts on the biofilm matrix structure itself, penetrates through the biofilm barrier, targets embedded bacteria, and prevents new biofilm formation simultaneously. This multi-dimensional approach ensures that biofilm protection does not shield bacteria from effective treatment.
4Reliability
If resistance mechanisms are activated by bacteria, then survival is improved, but the development of further resistant strains is facilitated
Solution Approach 1:
The patent applies preliminary anti-action by designing molecules that preemptively counteract resistance mechanisms before they can be selected for. The multi-target design ensures that even if bacteria develop resistance to one mechanism, other mechanisms remain effective, thereby preventing the evolution of comprehensive resistance and maintaining bacterial survival without facilitating resistance development.
Solution Approach 2:
The patent employs composite molecular structures that combine multiple functional moieties within a single agent, each targeting different bacterial processes or resistance mechanisms. This composite approach ensures that resistance to one component does not confer resistance to the entire agent, thereby maintaining effectiveness against evolving resistant strains while supporting bacterial survival through diverse mechanisms.
Data Source
AI summary
The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.